NCT00057317View on ClinicalTrials.gov

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2001

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Diabetes
Interventions
DRUG

Ro 205-2349

Trial Locations (117)

1233

Sofia

1431

Sofia

2000

Ploieşti

2900

Arad

3036

Kaunas

3040

Kaunas

3042

Kaunas

3100

Tukums

3201

Talsi

4002

Plovdiv

4300

Târgu Mureş

5001

Ogre

5800

Pleven

6200

Galati

7000

Bucharest

10138

Tallinn

11040

New Hyde Park

14050

Mexico City

14209

Buffalo

14609

Rochester

15425

Connellsville

17011

Camp Hill

19104

Philadelphia

19107

Philadelphia

19713

Newark

22320

Tijuana

23294

Richmond

23451

Virginia Beach

24266

Lebanon

27560

Morrisville

27710

Durham

28209

Charlotte

29651

Greer

30045

Lawrenceville

30322

Atlanta

32204

Jacksonville

33021

Hollywood

33401

West Palm Beach

34471

Ocala

35801

Huntsville

38119

Memphis

42039

Pachuca, Hidalgo

44280

Guadalajara

44349

Guadalajara

50406

Tartu

50708

Tartu

59101

Billings

63104

St Louis

63110

St Louis

64111

Kansas City

64320

Monterrey

64410

Monterrey

64460

Monterrey

65609

Võru

66211

Overland Park

70121

New Orleans

75230

Dallas

77030

Houston

78229

San Antonio

78284

San Antonio

79705

Midland

79902

El Paso

85206

Mesa

85251

Scottsdale

85710

Tucson

85723

Tucson

87106

Albuquerque

89102

Las Vegas

91106

Pasadena

91436

Encino

92618

Irvine

92708

Fountain Valley

93720

Fresno

94066

San Bruno

94086

Sunnyvale

94538

Fremont

95355

Modesto

95405

Santa Rosa

96813

Honolulu

97000

Mérida

97062

Tualatin

97201

Portland

98026

Edmonds

98801

Wenatchee

500326

Brasov

06518

Hamden

06850

Norwalk

46214-2985

Indianapolis

02215

Boston

68198-3032

Omaha

08611

Trenton

27858-4354

Greenville

02914

East Providence

78229-4801

San Antonio

T3B 0M3

Calgary

R3E 3P4

Winnipeg

B3H 1V7

Halifax

L1E 3C3

Courtice

K1Y 4E9

Ottawa

N8X 1K4

Windsor

H7T 2P5

Laval

H1T 2M4

Montreal

H3T 1E2

Montreal

G1V 4G2

Sainte-Foy

J1G 5K2

Sherbrooke

A1B 3V6

St. John's

LV-4201

Valmiera

Unknown

Vilnius

Panama City

03100

Mexico City

06700

Mexico City

00732-7994

Ponce

020475

Bucharest

0200

Târgovişte

RG12 1HX

Bracknell

NG2 3HF

Nottingham

PL6 8BX

Plymouth

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00057317 - Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter